MKI67 and neoplasm: Kaplan-Meier analysis (median follow-up, 16.3 months; range, 5-62 months; Figure 2) revealed better survival in patients with a low percentage of Ki67+ tumor cells (P<0.001, ≤5% vs. >5%) or low IOD of FMRP+ cells (P<0.01, ≤30 vs. >30).